Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Hyodeoxycholic Acid Suppresses Hepatosteatosis via GLP-1/iNKT Cell Crosstalk and PPARα Activation (scRNAseq_CD4+ lymphocytes)

ABSTRACT: Hepatosteatosis, a common liver condition, involves excessive lipid accumulation and can lead to severe complications. Its molecular mechanisms are poorly understood, highlighting the need for therapies. The molecular mechanisms are poorly understood, emphasizing the need for effective therapies. In this study, we identified hyodeoxycholic acid (HDCA) as a potent anti-steatotic agent capable of preventing diet-induced fatty liver. Mechanistically, HDCA treatment enhanced the hepatic expression of numerous PPARα target genes while also promoting the secretion of the gut hormone GLP-1. The significance of PPARα signalling was emphasised by the fact that the anti-steatotic effects of HDCA were completely abolished in PPARα-knockout mice. Our findings further reveal a novel mechanism involving invariant natural killer T (iNKT) cells. HDCA treatment increased both the number and proliferation of iNKT cells in vivo, a phenomenon recapitulated in vitro using a GLP-1 agonist. This indicates that the anti-steatotic action of HDCA requires the coordinated activity of PPARα signalling and iNKT cells. These insights offer a promising avenue for developing targeted therapies for MASLD.

ORGANISM(S): Mus musculus

PROVIDER: GSE288229 | GEO | 2026/07/13

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Hyodeoxycholic Acid Suppresses Hepatosteatosis via GLP-1/iNKT Cell Crosstalk and PPARα Activation (scRNAseq_primary hepatocytes)

Project description:Hepatosteatosis, a common liver condition, involves excessive lipid accumulation and can lead to severe complications. Its molecular mechanisms are poorly understood, highlighting the need for therapies. The molecular mechanisms are poorly understood, emphasizing the need for effective therapies. In this study, we identified hyodeoxycholic acid (HDCA) as a potent anti-steatotic agent capable of preventing diet-induced fatty liver. Mechanistically, HDCA treatment enhanced the hepatic expression of numerous PPARα target genes while also promoting the secretion of the gut hormone GLP-1. The significance of PPARα signalling was emphasised by the fact that the anti-steatotic effects of HDCA were completely abolished in PPARα-knockout mice. Our findings further reveal a novel mechanism involving invariant natural killer T (iNKT) cells. HDCA treatment increased both the number and proliferation of iNKT cells in vivo, a phenomenon recapitulated in vitro using a GLP-1 agonist. This indicates that the anti-steatotic action of HDCA requires the coordinated activity of PPARα signalling and iNKT cells. These insights offer a promising avenue for developing targeted therapies for MASLD.

2026-07-13 | GSE288750 | GEO

Hyodeoxycholic Acid Suppresses Hepatosteatosis via GLP-1/iNKT Cell Crosstalk and PPARα Activation (Bulk RNA-seq)

2026-07-13 | GSE288227 | GEO

HDCA binding proteins

Project description:To elucidate the molecular mechanism behind the anti-NAFLD effect of HDCA, we screened for potential HDCA binding proteins using biotin-labeled HDCA and HuProt human proteome microarray.

2023-08-17 | GSE241065 | GEO

Hyodeoxycholic Acid Suppresses Hepatosteatosis via GLP-1/iNKT Cell Crosstalk and PPARα Activation (scRNAseq_CD4+ lymphocytes)

Project description:Hyodeoxycholic Acid Suppresses Hepatosteatosis via GLP-1/iNKT Cell Crosstalk and PPARα Activation (scRNAseq_CD4+ lymphocytes)

| PRJNA1216595 | ENA

Hyodeoxycholic Acid Suppresses Hepatosteatosis via GLP-1/iNKT Cell Crosstalk and PPARα Activation (scRNAseq_primary hepatocytes)

Project description:Hyodeoxycholic Acid Suppresses Hepatosteatosis via GLP-1/iNKT Cell Crosstalk and PPARα Activation (scRNAseq_primary hepatocytes)

| PRJNA1219191 | ENA

Hyodeoxycholic Acid Suppresses Hepatosteatosis via GLP-1/iNKT Cell Crosstalk and PPARα Activation (Bulk RNA-seq)

Project description:Hyodeoxycholic Acid Suppresses Hepatosteatosis via GLP-1/iNKT Cell Crosstalk and PPARα Activation (Bulk RNA-seq)

| PRJNA1216600 | ENA

GLP-1R and GIPR heterodimerization and expression determine downstream signaling and metabolic phenotypes

Project description:Advancements in unimolecular drugs co-targeting the glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) have demonstrated remarkable clinical efficacy in treating type 2 diabetes (T2D) and obesity. However, the paradoxical ability of both GIPR agonism and antagonism to complement GLP-1R agonism underscores the need to elucidate molecular mechanisms underlying incretin receptor pharmacology and crosstalk. Here, we show that GLP-1 promotes heterodimerization via interactions between TM4 of GLP-1R and TM1/2 of GIPR. Phosphoproteomics profiling and molecular dynamics simulations reveal that dimerizing and non-dimerizing GLP-1R agonists differentially engage with GLP-1R and elicit distinct regulation of downstream signaling networks in human islets. Co-expression of GLP-1R and GIPR amplifies GIPR-mediated signaling in a β-arrestin-dependent manner, while GLP-1R-mediated signaling is suppressed by GIPR expression. Additionally, upregulation or downregulation of GIPR expression was associated with adiposity and diabetic traits, respectively. Collectively, these findings uncover mechanisms underlying the interplay between GLP-1R and GIPR and highlight heterodimerization as an innovative strategy for incretin-based therapies and personalized treatment.

2026-05-13 | PXD063931 | Pride

Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy

Project description:Invariant natural killer T (iNKT) cells are a distinct subset of T lymphocytes that possess unique properties making them highly suitable for addressing the challenges of solid tumor immunotherapy. Unlike conventional T cells, which are restricted by polymorphic major histocompatibility complex (MHC) molecules and recognize peptide antigens, iNKT cells are restricted by the non-polymorphic CD1d molecule and respond to lipid antigens. Chimeric antigen receptor (CAR)-redirected iNKT (CAR-iNKT) cells represent a significant advancement in cancer immunotherapy. However, optimizing sustained activation and long-term persistence of CAR-iNKT cells remains a critical need for effective solid tumor treatment. To address these limitations, we develop the iNKT cell-targeted microparticle recruitment and activation system (iMRAS), a biomimetic platform designed to enhance iNKT cell functionality through localized immunostimulation in vivo. This biomimetic platform is designed to function as an in vivo “charging station” containing chemotactic and activation signals for the recruitment, activation, and expansion of CAR-iNKT cells, leading to more effective tumor killing and longer persistence of CAR-iNKT cells, as demonstrated in the therapy of lymphoma and melanoma. Through its biomimetic design and localized immunostimulatory effects, iMRAS helps overcome the limitations of current therapies for solid tumors, establishing a robust platform for enhancing systemic CAR-iNKT cell-mediated immunotherapy.

2025-05-07 | GSE291443 | GEO

RNA-seq of group 1 Innate Lymphoid Cells (ILCs) in the mouse uterus and liver

Project description:We identified differences in the distribution of three group 1 ILC subsets in the mouse uterus. The dynamic distribution of g1 ILC subsets in the uterus at key stages of reproductive life may reflect subset-specific functions and emphasised the need for detailed characterisation of each subset

2018-10-05 | E-MTAB-6812 | biostudies-arrayexpress

Comprehensive analysis of PPARα-dependent regulation of hepatic lipid metabolism by expression profiling - 3

Project description:PPARα is a ligand-activated transcription factor involved in the regulation of nutrient metabolism and inflammation. Although much is already known about the function of PPARα in hepatic lipid metabolism, many PPARα-dependent pathways and genes have yet to be discovered. In order to obtain an overview of PPARα-regulated genes relevant to lipid metabolism, and to probe for novel candidate PPARα target genes, livers from several animal studies in which PPARα was activated and/or disabled were analyzed by Affymetrix GeneChips. Numerous novel PPARα-regulated genes relevant to lipid metabolism were identified. Out of this set of genes, eight genes were singled out for study of PPARα-dependent regulation in mouse liver and in mouse, rat, and human primary hepatocytes, including thioredoxin interacting protein (Txnip), electron-transferring-flavoprotein β polypeptide (Etfb), electron-transferring-flavoprotein dehydrogenase (Etfdh), phosphatidylcholine transfer protein (Pctp), endothelial lipase (EL, Lipg), adipose triglyceride lipase (Pnpla2), hormone-sensitive lipase (Lipe), and monoglyceride lipase (Mgll). Using an in silico screening approach, one or more PPAR response elements (PPREs) were identified in each of these genes. Since Pnpla2, Lipe, and Mgll contribute to hepatic triglyceride hydrolysis, gene regulation was studied under conditions of elevated hepatic lipids. In wild-type mice fed a high fat diet, the decrease in hepatic lipids following treatment with the PPARα agonist Wy14643 was paralleled by significant up-regulation of Pnpla2, Lipe, and Mgll, suggesting that induction of triglyceride hydrolysis may contribute to the anti-steatotic role of PPARα. Our study illustrates the power of transcriptional profiling to uncover novel PPARα-regulated genes and pathways in liver. Keywords: identification of target genes

2007-07-24 | GSE8292 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data